Ozempic Face, Loose Skin and Hair Loss on GLP-1: What the Evidence Shows

Updated October 2026

“Ozempic face” has become a popular term for facial hollowing, reduced fullness, wrinkles and looser-looking skin after substantial weight loss. Hair shedding and loose skin have also become common concerns among people taking GLP-1 medicines such as semaglutide and tirzepatide.

The important question is whether these changes are caused directly by the medication or whether they are primarily consequences of losing a substantial amount of body fat.

The evidence is more nuanced than social media suggests. Rapid or substantial weight loss can change facial fat compartments, skin tension and body composition. Hair shedding can occur during major weight loss and is commonly described as telogen effluvium. Current U.S. FDA labeling for Wegovy and Zepbound recognizes hair loss as an adverse reaction associated with weight reduction. By contrast, “Ozempic face” is not a formal diagnosis and there is not strong clinical evidence showing that Ozempic uniquely accelerates facial aging.

What the evidence shows

Ozempic face Facial volume loss and increased skin laxity can occur after substantial weight loss. The term describes an appearance, not a specific disease.

Loose skin Losing fat reduces the volume underneath stretched skin. Age, genetics, duration of obesity, total weight lost and skin elasticity influence how much laxity remains.

Hair loss Hair shedding can accompany rapid weight loss, calorie restriction and nutritional inadequacy. The pattern is often consistent with telogen effluvium.

Bottom line: GLP-1 therapy does not necessarily “damage” the face, skin or hair. Much of what people notice may be the visible consequence of successful fat loss. However, the magnitude and speed of weight loss, nutritional intake and individual biology can make these effects more noticeable.

What Is “Ozempic Face”?

“Ozempic face” is a media and cosmetic term rather than a medical diagnosis. It generally refers to a face that appears thinner, more hollow, more wrinkled or less firm after significant weight loss.

When body fat decreases, fat is lost from multiple anatomical compartments. This includes fat in the cheeks, temples, lower face and other areas that contribute to facial fullness. A systematic review of facial changes after massive weight loss found notable facial fat-volume reduction, particularly in the mid-cheek region, together with increased skin laxity. PubMed: Soft Tissue Facial Changes Following Massive Weight Loss.

Newer 2026 reviews specifically examining GLP-1-associated weight loss describe facial hollowing, contour changes and laxity as important aesthetic consequences of substantial weight reduction, while also emphasizing that better long-term studies are still needed. PubMed: GLP-1-Induced Weight Loss and the Face.

Does Ozempic Actually Cause Facial Aging?

The answer is not established in the simple way the phrase “Ozempic face” implies.

Ozempic contains semaglutide and is FDA-approved for specific indications in adults with type 2 diabetes. The current U.S. label does not identify “facial aging” or “Ozempic face” as a defined adverse reaction. FDA Ozempic Prescribing Information.

The more convincing explanation is that rapid or substantial loss of subcutaneous fat changes the architecture of the face. The same phenomenon can occur after bariatric surgery, intensive dieting or other substantial weight-loss interventions.

A 2024 systematic review of facial soft-tissue changes after massive weight loss found that weight loss is associated with facial fat-volume reduction and skin laxity. A 2026 review of weight-loss drugs similarly concluded that rapid weight reduction can create challenges involving facial volume and skin laxity, while noting that GLP-1-specific evidence remains limited. Facial Soft-Tissue Systematic Review · 2026 Review of Weight-Loss Drugs and Facial Aesthetics.

Evidence assessment: E3–E4
The association between major weight loss and facial volume/laxity is supported by systematic and clinical literature. Direct evidence proving that semaglutide itself causes accelerated facial aging independently of weight loss is substantially weaker.

Why Does the Face Look Older After Weight Loss?

Several changes can happen at the same time.

1. Loss of facial fat volume

Subcutaneous facial fat provides fullness and support. When this volume decreases, cheeks and temples can look flatter and facial contours can become more pronounced.

That can make pre-existing wrinkles, nasolabial folds or under-eye hollowness appear more visible even though the underlying process is primarily volume reduction rather than necessarily accelerated biological aging.

2. Skin has less underlying volume

Skin that has stretched over years of overweight or obesity does not always contract completely after the underlying fat compartment shrinks.

The result may be looser skin around the cheeks, jawline, neck, arms, abdomen and thighs.

3. Loss of lean tissue can change contours

Weight loss is not exclusively fat loss. GLP-1 therapies can also reduce lean mass, although fat generally represents the larger component of weight lost.

In the exploratory DXA substudy of STEP 1, semaglutide 2.4 mg produced substantial reductions in fat mass and lean body mass. The researchers reported a larger proportional reduction in fat mass than in lean mass and an increase in the proportion of body weight represented by lean mass. STEP 1 — NEJM.

A key limitation is that DXA lean mass is not the same thing as skeletal muscle. It also includes water and other non-fat tissues. Therefore, saying that “40% of the weight lost is muscle” is an oversimplification.

How Much Lean Mass Is Lost on GLP-1 Drugs?

This question matters because preserving lean tissue may influence strength, function, body shape and long-term weight management.

Semaglutide — STEP 1 DXA substudy Semaglutide reduced both fat mass and lean body mass. The study found that fat loss was the larger component, but measurable lean-mass reduction also occurred.

Tirzepatide — SURMOUNT-1 In a DXA substudy, body weight fell 21.3%, fat mass 33.9% and lean mass 10.9% with tirzepatide over 72 weeks. Approximately 75% of weight lost was fat mass and 25% lean mass.

Clinical interpretation Lean-mass loss deserves attention, but DXA cannot determine exactly how much of the lost lean mass was skeletal muscle. Function and strength are more meaningful than the scale alone.

The tirzepatide findings come from a 160-person body-composition substudy of SURMOUNT-1. Approximately three-quarters of the weight lost was fat mass and one-quarter was lean mass. PubMed: SURMOUNT-1 Body Composition.

Recent reviews of incretin-based therapies consistently conclude that fat mass is the predominant component of weight loss, although absolute lean-mass reductions can occur. 2026 Systematic Review and Meta-Analysis of Lean Mass Changes.

Does More Weight Loss Mean More “Ozempic Face”?

Not necessarily in a simple one-to-one relationship, but larger and faster changes in body composition give the face less time to adapt.

People can have dramatically different facial changes after the same amount of weight loss. Age, genetics, skin elasticity, sun exposure, smoking history, baseline facial volume, duration of obesity and where an individual stores and loses fat all matter.

Someone losing 10 kg slowly may look very different from someone losing 20 kg rapidly. The same total weight loss can produce very different facial outcomes between two individuals.

What Causes Loose Skin After GLP-1 Weight Loss?

Loose skin is primarily a structural consequence of losing the tissue that previously filled and stretched the skin.

Skin contains collagen, elastin and other extracellular-matrix components that determine elasticity and mechanical strength. After substantial weight loss, the skin may not completely recoil to its previous contour.

A 2026 review of the soft-tissue consequences of rapid weight loss noted changes in skin firmness, muscle mass and other structural tissues. PubMed: Weight Loss and Its Impact on Soft Tissue.

Importantly, loose skin is not evidence that the medication is toxic to the skin. It can be a consequence of a successful reduction in body volume.

Can You Prevent Loose Skin on GLP-1?

You cannot completely prevent loose skin. Skin elasticity is highly individual, and once substantial excess skin has developed, exercise or a cream cannot reliably remove it.

However, several strategies can improve the overall appearance and help protect muscle and skin health during weight loss.

1. Avoid unnecessary crash dieting Follow the prescribed dose-escalation plan rather than trying to accelerate weight loss beyond the treatment plan.

2. Prioritize adequate protein Adequate dietary protein helps support lean tissue during weight loss. Individual requirements vary by body size, age, kidney function and activity level.

3. Perform resistance training Strength training provides a stimulus to maintain or build muscle while body weight is falling.

4. Stay adequately hydrated Hydration supports normal skin function and is especially important when gastrointestinal adverse effects reduce food and fluid intake.

5. Protect skin from ultraviolet exposure Sun protection helps reduce additional collagen and elastin damage and is a basic component of skin aging prevention.

6. Give your body time to adapt Some people find that skin appearance changes as weight stabilizes, although substantial excess skin may persist.

Recent dermatology guidance recommends hydration, moisturizer, sun protection and appropriate skin care for people using GLP-1 drugs. However, these measures should not be marketed as guaranteed methods of removing excess skin. American Academy of Dermatology: GLP-1 Drugs and Skin, Hair and Nails.

What About “Crepey” Skin?

Crepey or finely wrinkled skin can become more noticeable after fat loss because there is less underlying volume and because previously stretched skin may not fully contract.

Moisturizers can improve hydration and surface appearance. Sunscreen can protect against additional photoaging. Some topical ingredients may improve the appearance of fine lines over time, but no topical cream has been shown to reliably restore the volume of fat lost from the face.

A 2026 review suggests topical skincare may have a supporting role in managing post-weight-loss skin quality, but it also emphasizes that larger clinical studies are needed. PubMed: Topical Skincare After GLP-1 Use and Rapid Weight Loss.

Does Ozempic Cause Hair Loss?

Hair shedding can occur during GLP-1-associated weight loss, but the mechanism is not completely established.

The most plausible explanation for many cases is telogen effluvium, a temporary shift in the hair-growth cycle that can follow physiological stress, significant weight loss, illness, surgery or major dietary changes.

The American Academy of Dermatology specifically notes that hair thinning can occur in people taking GLP-1 drugs and says dermatologists believe the sudden weight loss is an important contributor. The AAD also notes that reduced food intake can make it harder to obtain enough protein and nutrients needed for healthy hair growth. AAD: How GLP-1 Drugs Affect Skin, Hair and Nails.

What Do the FDA Labels Say About Hair Loss?

This is one area where the evidence is clearer than the “Ozempic face” discussion.

Wegovy (semaglutide) The current FDA labeling reports hair loss in 3.3% of adults treated with Wegovy 2.4 mg compared with 1.0% receiving placebo in pooled weight-management studies. The label states that the hair loss adverse reactions were associated with weight reduction.

Zepbound (tirzepatide) The FDA label states that hair loss was associated with weight reduction. In pooled trials, reported hair loss was more common in women than men: 7.1% versus 0.5% with Zepbound, compared with 1.3% and 0% with placebo.

Ozempic The current FDA Ozempic label lists gastrointestinal adverse reactions as the most common adverse effects but does not list hair loss among the common adverse reactions in the highlighted prescribing information.

FDA Wegovy Label · FDA Zepbound Label · FDA Ozempic Label.

Evidence assessment: E5 for the existence of the adverse-event signal; E3/E2 for mechanism and causality.
Hair loss is documented in clinical-trial labeling for Wegovy and Zepbound. The labeling itself associates the reaction with weight reduction. This does not prove that semaglutide or tirzepatide directly damages hair follicles.

Why Does Hair Shedding Often Start Months Later?

Telogen effluvium usually does not appear immediately after the trigger.

After a physiological stressor such as substantial weight loss, more hair follicles can enter the resting phase. Increased shedding may therefore become noticeable several weeks to a few months later rather than on the day weight loss begins.

The American Academy of Dermatology notes that excessive shedding commonly occurs a few months after the triggering event and can gradually resolve as the body readjusts. AAD: Hair Shedding and Telogen Effluvium.

A review of telogen effluvium similarly describes sudden weight loss as a recognized physiological trigger. PubMed: Telogen Effluvium Review.

Is GLP-1 Hair Loss Permanent?

Not necessarily.

When the cause is acute telogen effluvium, excessive shedding is usually temporary. As the physiological stressor resolves, the hair cycle can normalize and fullness can gradually return.

The American Academy of Dermatology notes that when a stress-related shedding trigger resolves, many people regain normal fullness within approximately six to nine months. AAD: Telogen Effluvium.

However, not every person taking a GLP-1 who loses hair has telogen effluvium. Pattern hair loss, androgenetic alopecia, alopecia areata, thyroid disorders, iron deficiency and other causes can coexist with weight-loss-associated shedding.

When Hair Loss Needs Medical Evaluation

Do not automatically assume that every case of hair loss is caused by a GLP-1 medication.

Patchy bald spots Round or clearly defined patches can suggest a different type of alopecia.

Scalp inflammation Pain, scaling, redness, pustules or significant itching deserve assessment.

Persistent shedding Hair loss that continues or progressively worsens despite stabilization of weight deserves evaluation.

Major nutritional change Very low food intake, restrictive dieting or significant gastrointestinal symptoms may increase nutritional risk.

Other symptoms Fatigue, weakness, menstrual changes or other systemic symptoms can indicate a cause unrelated to the GLP-1 drug itself.

Patterned thinning A widening part, receding hairline or gradual thinning may indicate hereditary hair loss rather than simple telogen effluvium.

A dermatologist can distinguish excessive shedding from other forms of alopecia and determine whether blood testing or treatment is appropriate. AAD: Hair Loss Diagnosis and Treatment.

Should You Take Biotin, Iron or “Hair Vitamins”?

This is an area where aggressive supplement marketing frequently gets ahead of the evidence.

More is not automatically better. Taking large doses of nutrients without a demonstrated need can be ineffective and, in some situations, harmful.

The American Academy of Dermatology specifically cautions that excessive amounts of certain nutrients can worsen hair loss. AAD: Hair Loss Treatment Tips.

For people with substantial hair shedding, a clinician may consider the overall diet, medical history and selected laboratory tests. Depending on the individual situation, evaluation can include iron status, thyroid function or other nutritional and medical factors.

Iron should not be taken simply because hair is shedding. Treating documented deficiency is different from taking high-dose iron without evidence of deficiency.

Does Protein Help Prevent GLP-1 Hair Loss?

Protein is important because hair is a protein-based structure and insufficient dietary intake can contribute to nutritional stress during major weight loss.

There is also a separate reason to focus on protein: preserving lean tissue is important during weight reduction.

However, there is no strong clinical trial evidence showing that a particular protein intake completely prevents GLP-1-associated hair loss.

The practical goal is adequate nutrition rather than extreme protein loading. People with kidney disease or other medical conditions may require individualized dietary targets.

Can Resistance Training Reduce the “Ozempic Face” Effect?

Resistance training cannot selectively rebuild lost facial fat, so it should not be promoted as a direct cure for Ozempic face.

Its more important role is preserving or increasing skeletal muscle elsewhere in the body during weight loss.

Maintaining muscle can improve body composition and physical function and may reduce some of the “deflated” appearance associated with substantial weight loss. Current evidence on incretin therapies supports pairing weight-loss treatment with strategies focused on lean-mass preservation. 2026 Meta-Analysis of Lean Mass Changes With Incretin Therapy.

What About Collagen Supplements?

Collagen supplements are frequently marketed specifically for people experiencing loose skin during GLP-1 treatment.

There is some research on oral collagen and skin parameters in other contexts, but there is not sufficient evidence to claim that collagen supplements prevent or reverse GLP-1-associated facial volume loss or substantial excess skin.

The distinction is important: improving a skin-quality measure is not the same as replacing lost facial fat or surgically removing excess skin.

Can Creams Tighten Loose Skin?

Moisturizers can improve skin hydration, texture and the appearance of dryness. Certain topical ingredients may improve fine lines over time.

But a cream cannot reliably remove a large amount of excess skin created by major weight loss.

People should be particularly skeptical of products promising to “reverse Ozempic face” or permanently tighten substantial loose skin without procedures.

What Treatments Are Available for Ozempic Face?

Treatment depends on what has actually changed: volume loss, fine lines, skin laxity, pigmentation or true excess skin.

Skin care Moisturizer, sun protection and carefully selected topical products can improve skin quality and the appearance of fine lines.

Energy-based treatments Radiofrequency, ultrasound and laser-based approaches are sometimes used to improve skin tightening or texture. Results vary and GLP-1-specific evidence remains limited.

Dermal fillers Hyaluronic-acid fillers can restore selected areas of lost facial volume when appropriate.

Biostimulatory treatments Some injectable treatments aim to stimulate collagen production rather than simply add volume.

Fat transfer Autologous fat can be used to restore volume in selected patients.

Surgery For significant excess skin, surgical procedures may provide the greatest structural correction. The decision depends on anatomy, health, goals and weight stability.

The American Academy of Dermatology lists fillers, fat transfer, laser treatments and platelet-rich plasma among approaches used by dermatologists for facial changes following GLP-1-associated weight loss. However, evidence specifically testing these procedures in GLP-1-treated populations remains limited. AAD: GLP-1 Drugs and Skin, Hair and Nails.

Should You Stop Ozempic or Wegovy Because of Ozempic Face?

Do not stop or change a prescribed GLP-1 medication solely because of an appearance-related concern without discussing it with the prescribing clinician.

For an appropriate patient, GLP-1 therapy can provide substantial improvements in weight, glycemic control and cardiometabolic health. The cosmetic effects of weight loss need to be considered alongside those health benefits.

The American Academy of Dermatology likewise emphasizes that the health benefits of GLP-1 medicines in appropriate patients can outweigh their dermatologic disadvantages. AAD Clinical Guidance.

Ozempic Face vs Loose Skin vs Hair Loss

Ozempic face Usually refers to facial volume loss, hollowing, wrinkles or laxity following substantial weight loss.

Main driver: reduced facial fat volume and changes in soft-tissue support.

Loose skin Refers to redundant or lax skin that remains after underlying body volume decreases.

Main drivers: magnitude of weight loss, duration of tissue stretching, age, genetics and skin elasticity.

Hair shedding Often refers to diffuse increased shedding that may occur after physiological stress or rapid weight loss.

Common explanation: telogen effluvium, although other diagnoses are possible.

Evidence Grading: How Strong Is the Evidence?

E5 — Regulatory / Clinical Trial Evidence FDA labeling documents hair loss as an adverse reaction with Wegovy and Zepbound and links the event to weight reduction.

E4 — Randomized Controlled Trial Evidence Major trials such as STEP and SURMOUNT provide strong evidence that semaglutide and tirzepatide can produce substantial weight loss and measurable changes in body composition.

E3 — Systematic Reviews Reviews of facial soft tissue, lean mass and dermatologic effects support an association between substantial weight loss and changes in facial volume, skin laxity and body composition.

E2 — Observational / Pharmacovigilance Evidence Real-world reports and pharmacovigilance databases provide signals for hair loss but cannot establish causality on their own.

E1 — Mechanistic Evidence Proposed effects involving adipose tissue, collagen, fibroblasts and the hair-growth cycle remain biologically interesting but are not sufficient to prove a direct drug-specific mechanism in humans.

E0 — Anecdotal Evidence Social-media photographs and individual testimonials can illustrate what people experience but cannot determine whether a GLP-1 drug caused the change.

The Biggest Myth About “Ozempic Face”

The biggest misconception is that everyone taking Ozempic or another GLP-1 drug will develop a prematurely aged face.

That is not supported by current evidence.

Many people lose weight without developing a dramatic cosmetic change. Others experience substantial facial deflation. There is no reliable facial-ageing threshold at which a particular drug automatically causes “Ozempic face.”

The appearance depends on the individual's starting anatomy, the amount and rate of weight loss, age, skin quality, genetics and the distribution of lost fat.

What About the Phrase “GLP-1 Face”?

“GLP-1 face” is arguably a more accurate umbrella term than “Ozempic face” when discussing the cosmetic effects associated with modern weight-loss pharmacotherapy.

Semaglutide, tirzepatide and other incretin-based medicines can produce significant weight reduction. Similar facial effects can theoretically occur whenever large amounts of subcutaneous fat are lost, regardless of whether that weight loss occurs through medication, bariatric surgery or lifestyle intervention.

That is why it is better to discuss post-weight-loss facial changes rather than implying that Ozempic has a unique facial-aging toxicity.

How to Reduce the Risk of Unwanted Cosmetic Changes During GLP-1 Weight Loss

1. Follow the prescribed titration schedule. Do not increase dosing to accelerate weight loss without medical supervision.
2. Eat enough to meet nutritional needs. Severe calorie restriction can increase nutritional stress.
3. Prioritize adequate protein. Consider individual needs rather than following a one-size-fits-all target.
4. Perform resistance exercise. Focus on maintaining strength and lean tissue.
5. Stay hydrated. Particularly important if nausea, vomiting, diarrhea or reduced food intake is present.
6. Protect your skin. Use moisturizer and broad-spectrum sunscreen and avoid unnecessary UV exposure.
7. Do not automatically take high-dose supplements. Correct deficiencies when clinically indicated.
8. Monitor the rate and quality of weight loss. The scale is not the only important outcome.
9. Discuss significant hair shedding with a dermatologist. A correct diagnosis is more useful than assuming the GLP-1 is the only cause.

When to Contact Your Healthcare Team

Contact your prescribing clinician or another qualified healthcare professional when you have significant unintended weight loss, persistent vomiting or diarrhea, difficulty maintaining adequate nutrition or hydration, marked weakness, or other concerning symptoms.

For hair concerns, seek dermatologic evaluation when shedding is severe, persistent, patchy, associated with scalp inflammation, or accompanied by other symptoms.

For loose skin, medical evaluation is appropriate when folds repeatedly become inflamed, infected or painful, or when excess skin interferes with mobility, hygiene or daily activities.

Frequently Asked Questions

Does Ozempic cause “Ozempic face”?

There is no medical diagnosis called Ozempic face and no strong evidence that Ozempic uniquely causes facial aging. The appearance most often discussed under this label is facial volume loss, wrinkling or laxity associated with substantial weight loss. A direct drug-specific contribution remains an area of ongoing research.

Is Ozempic face permanent?

It depends on the person and what has changed. Some visible changes may settle as weight stabilizes, but substantial loss of facial fat or significant excess skin may persist. Cosmetic treatments can address selected structural changes when appropriate.

Does Ozempic cause loose skin?

Substantial weight loss can produce loose skin because the skin may not completely contract after the underlying body volume decreases. This is not unique to Ozempic and can occur after other forms of major weight loss.

Does semaglutide cause hair loss?

Hair loss is reported with semaglutide treatment for weight management and is included in current Wegovy FDA labeling. The label states that hair loss adverse reactions were associated with weight reduction. The mechanism is not completely established, and telogen effluvium following physiological stress or rapid weight loss is an important possible explanation.

How long does GLP-1 hair shedding last?

When shedding is telogen effluvium, it is usually temporary and tends to improve after the trigger resolves. Hair recovery can take months. Persistent or progressive hair loss should be evaluated because other forms of alopecia may be present.

Can protein prevent hair loss on Ozempic?

Adequate protein supports normal hair growth and helps preserve lean tissue during weight loss, but there is not enough evidence to say that a particular protein intake will completely prevent GLP-1-associated hair shedding.

Can collagen supplements prevent Ozempic face?

There is insufficient evidence to claim that collagen supplements prevent or reverse the facial volume loss commonly described as Ozempic face. Nutrition and skin care may support general skin health, but they cannot reliably replace lost facial fat.

Should I stop my GLP-1 because of hair loss?

Do not stop a prescribed medication on your own. Discuss the severity of the hair loss with your prescriber and consider dermatologic evaluation to determine whether the cause is telogen effluvium, nutritional deficiency, hereditary hair loss or another condition.

Final Verdict

“Ozempic face,” loose skin and hair shedding are real concerns, but the evidence is more reassuring and more complicated than the headlines suggest.

For facial appearance and loose skin, the strongest explanation is the physical effect of substantial weight loss: less subcutaneous fat means less facial and body volume, which can expose wrinkles and leave previously stretched skin looser.

For hair, the evidence is stronger that an association exists. Current FDA labeling documents hair loss with Wegovy and Zepbound and states that the events were associated with weight reduction. Rapid weight loss, calorie restriction and nutritional stress can trigger telogen effluvium, which is often temporary.

The most evidence-based strategy is therefore not to fear weight loss, but to focus on the quality of weight loss: appropriate dosing, adequate nutrition, sufficient protein, resistance exercise, hydration, skin protection and medical evaluation when symptoms do not follow the expected pattern.

For people who are benefiting substantially from GLP-1 treatment, the potential metabolic and health benefits should be weighed against cosmetic concerns rather than allowing social-media terminology to substitute for individualized medical advice.

Medical disclaimer: This article is for educational purposes only and is not a substitute for diagnosis or personalized medical care. GLP-1 medicines should be used under appropriate medical supervision. Do not change, stop or increase a prescription medicine based solely on information in this article.

Evidence & References

1. FDA — Wegovy (semaglutide) Prescribing Information, 2026. Hair loss is reported in adults receiving Wegovy 2.4 mg and is described as associated with weight reduction. View FDA label.
2. FDA — Zepbound (tirzepatide) Prescribing Information, 2026. Hair loss is reported in clinical trials and is described as associated with weight reduction. View FDA label.
3. FDA — Ozempic (semaglutide) Prescribing Information, revised 2025. Current highlighted information lists the principal common adverse reactions and does not identify hair loss as a common adverse reaction. View FDA label.
4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. DOI: 10.1056/NEJMoa2032183. PubMed.
5. Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2025;27:2720-2729. DOI: 10.1111/dom.16275. PubMed.
6. Soft Tissue Facial Changes Following Massive Weight Loss Secondary to Medical and Surgical Bariatric Interventions: A Systematic Review. 2024. PubMed.
7. Barişkan S, et al. Losing Weight and Gaining Wrinkles: The Impact of Weight Loss Drugs on Facial Aesthetics. 2026. DOI: 10.1097/SCS.0000000000012582. PubMed.
8. Frank K, et al. GLP-1-Induced Weight Loss and the Face. Dermatologic Surgery. 2026. DOI: 10.1097/DSS.0000000000005180. PubMed.
9. Alopecia as an Emerging Adverse Effect Associated With GLP-1 Receptor Agonists for Weight Loss: A Scoping Review. 2025. PubMed.
10. American Academy of Dermatology — How can GLP-1 drugs affect my skin, hair, and nails? Updated 2026. AAD.
11. American Academy of Dermatology — Do you have hair loss or hair shedding? Guidance on telogen effluvium and stress-related shedding. AAD.
12. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2026. PubMed.

Related OneDayMD Resources

GLP-1 Knowledge graph: GLP-1 & Peptide Hub → Starting GLP-1 → muscle loss → bone density → nutrient monitoring → stopping GLP-1 → personalizing treatment → Next generation (GLP 2.0)